Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders.
Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders.
复制标题
喹硫平对患有广泛性发育障碍的儿童和青少年的回顾性研究。
DOI：
10.1007/s10803-005-3306-1
复制
发表时间：
2005
影响因子：
3.9
通讯作者：
Handen,BenjaminL
中科院分区：
文献类型：
--
作者：
Hardan,AntonioY;Jou,RogerJ;Handen,BenjaminL
A retrospective study was conducted in a clinic specialized in treating individuals with developmental disabilities to examine the effectiveness and tolerability of quetiapine in children and adolescents with pervasive developmental disorders. Ten consecutive outpatients (age = 12.0 ± 5.1 years) treated with quetiapine (dose = 477 ± 212 mg, duration = 22.0 ± 10.1 weeks) were identified and six were judged to be responders based on impressions from chart review and Conners Parent Scale (CPS). Improvements were observed in the conduct, inattention, and hyperactivity subscales of the CPS. Adverse events were mild with sedation being the most common, and no patient required treatment termination. Quetiapine may be beneficial in children and adolescents with pervasive developmental disorders, however open-label and double-blind, placebo-controlled studies are warranted.
